Politikos, Ioannis http://orcid.org/0000-0002-2854-8751
Devlin, Sean M.
Arcila, Maria E.
Barone, Jonathan C.
Maloy, Molly A.
Naputo, Kristine A.
Ruiz, Josel D.
Mazis, Christopher M. http://orcid.org/0000-0002-7490-2395
Scaradavou, Andromachi
Avecilla, Scott T. http://orcid.org/0000-0003-0661-9704
Dahi, Parastoo B. http://orcid.org/0000-0002-0794-3226
Giralt, Sergio A. http://orcid.org/0000-0003-1944-5053
Hsu, Katherine C. http://orcid.org/0000-0003-2827-5324
Jakubowski, Ann A.
Papadopoulos, Esperanza B.
Perales, Miguel A.
Sauter, Craig S.
Tamari, Roni
Ponce, Doris M.
O’Reilly, Richard J.
Barker, Juliet N.
Article History
Received: 16 March 2020
Revised: 7 June 2020
Accepted: 9 June 2020
First Online: 18 June 2020
Compliance with ethical standards
:
: IP has received research funding from Merck and serves on a Data and Safety Monitoring Board (DSMB) for ExCellThera. AS serves on a DSMB for ExcellThera and is the medical director of the New York Blood Center/National Cord Blood Program. STA has received honoraria from Abbott Laboratories. SAG has served as a consultant for Amgen, Actinium, Celgene, Johnson & Johnson, Jazz pharmaceutical, Takeda, Novartis, Kite, Spectrum Pharma and has received research funding from Amgen, Actinium, Celgene, Johnson & Johnson, Miltenyi, Takeda. MAP has received honoraria from Abbvie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, and Takeda; serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune; and has received research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi Biotec. CSS has served as a paid consultant on advisory boards for Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite, a Gilead Company, Celgene, Gamida Cell, Pfizer, and GSK, and has received research funding for clinical trials from Juno Therapeutics, Celgene, Precision Biosciences and Sanofi-Genzyme. RJOR receives royalties from Atara Biotherapeutics. JNB has received research funding from Angiocrine Bioscience, Gamida Cell, and Merck. The authors have no other relevant conflicts of interest to declare.